Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Shares Sold by Nantahala Capital Management LLC

Nantahala Capital Management LLC cut its stake in shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) by 20.0% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 2,340,333 shares of the company's stock after selling 583,688 shares during the quarter. Zevra Therapeutics comprises about 0.8% of Nantahala Capital Management LLC's investment portfolio, making the stock its 20th largest position. Nantahala Capital Management LLC owned approximately 4.38% of Zevra Therapeutics worth $19,518,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. IFG Advisors LLC boosted its stake in shares of Zevra Therapeutics by 10.0% during the 4th quarter. IFG Advisors LLC now owns 29,050 shares of the company's stock worth $242,000 after purchasing an additional 2,650 shares during the last quarter. Invesco Ltd. raised its stake in shares of Zevra Therapeutics by 19.6% in the 4th quarter. Invesco Ltd. now owns 18,384 shares of the company's stock valued at $153,000 after acquiring an additional 3,007 shares during the period. Corebridge Financial Inc. boosted its position in Zevra Therapeutics by 16.9% during the 4th quarter. Corebridge Financial Inc. now owns 26,294 shares of the company's stock worth $219,000 after purchasing an additional 3,801 shares during the period. Mystic Asset Management Inc. increased its holdings in Zevra Therapeutics by 1.9% in the 4th quarter. Mystic Asset Management Inc. now owns 313,347 shares of the company's stock valued at $2,613,000 after purchasing an additional 5,900 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD boosted its position in Zevra Therapeutics by 51.2% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 20,565 shares of the company's stock valued at $172,000 after buying an additional 6,966 shares during the last quarter. 35.03% of the stock is owned by institutional investors and hedge funds.

Zevra Therapeutics Trading Up 4.2 %

Shares of Zevra Therapeutics stock traded up $0.31 on Thursday, hitting $7.64. 743,479 shares of the company's stock traded hands, compared to its average volume of 614,493. Zevra Therapeutics, Inc. has a one year low of $4.20 and a one year high of $9.76. The company has a debt-to-equity ratio of 0.84, a current ratio of 2.88 and a quick ratio of 2.88. The company has a fifty day moving average of $7.49 and a two-hundred day moving average of $8.10. The company has a market capitalization of $417.75 million, a price-to-earnings ratio of -3.88 and a beta of 1.94.

Zevra Therapeutics (NASDAQ:ZVRA - Get Free Report) last released its earnings results on Tuesday, March 11th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.39) by ($0.28). The firm had revenue of $12.00 million during the quarter, compared to analysts' expectations of $8.93 million. Zevra Therapeutics had a negative return on equity of 159.54% and a negative net margin of 342.63%. As a group, sell-side analysts expect that Zevra Therapeutics, Inc. will post -1.95 earnings per share for the current year.

Insider Transactions at Zevra Therapeutics

In other news, Director John B. Bode acquired 10,000 shares of Zevra Therapeutics stock in a transaction dated Wednesday, March 19th. The stock was purchased at an average cost of $7.96 per share, with a total value of $79,600.00. Following the completion of the purchase, the director now directly owns 40,000 shares in the company, valued at approximately $318,400. This trade represents a 33.33 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO R. Laduane Clifton sold 11,000 shares of the firm's stock in a transaction on Thursday, February 13th. The shares were sold at an average price of $7.86, for a total transaction of $86,460.00. Following the transaction, the chief financial officer now directly owns 51,361 shares of the company's stock, valued at $403,697.46. The trade was a 17.64 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 85,773 shares of company stock worth $674,176. Insiders own 2.40% of the company's stock.

Analyst Upgrades and Downgrades

ZVRA has been the topic of several research reports. Citigroup reiterated an "outperform" rating on shares of Zevra Therapeutics in a research note on Wednesday, March 12th. HC Wainwright reaffirmed a "buy" rating and set a $20.00 target price on shares of Zevra Therapeutics in a research report on Thursday, March 13th. Canaccord Genuity Group boosted their target price on Zevra Therapeutics from $23.00 to $25.00 and gave the stock a "buy" rating in a research report on Thursday, March 13th. JMP Securities set a $18.00 price target on Zevra Therapeutics in a research report on Wednesday, March 12th. Finally, Guggenheim upped their price target on Zevra Therapeutics from $20.00 to $22.00 and gave the company a "buy" rating in a research report on Thursday, March 13th. Eight research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of "Buy" and an average target price of $22.29.

Zevra Therapeutics Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.